Breast Cancer

Latest News

Health equity text | Image Credit: Andrii - stock.adobe.com
Racial Inequities in Guideline-Adherent Breast Cancer Care and Timely Treatment

November 19th 2024

Older non-Hispanic Black adults with early-stage breast cancer are less likely to receive timely treatment and guideline-concordant care, increasing their risk of death compared with non-Hispanic White women.

Medicare Expansion | Image Credit: wladimir1804- stock.adobe.com
Breast Cancer Outcomes Improved in States With Medicaid Expansion

October 24th 2024

FDA Approved
FDA Approves Inavolisib in Locally Advanced, Metastatic Breast Cancer

October 11th 2024

Breast screening | Image Credit: Valerii Apetroaiei - stock.adobe.com
5 Things to Know Before a Breast Screening

October 11th 2024

Michael Hassett, MD, MPH, Dana-Farber Cancer Institute
Advancing Breast Cancer Care With HER2-Targeted Therapies

October 10th 2024

Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

Experts discuss the impact of CDK4/G inhibitor use, including medication cost, total care costs, toxicity profiles, and strategies to manage and optimize patient outcomes in high-risk early breast cancer.

Watch the latest AJMC Peer Exchange on Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

More News

Image depicting breast cancer
December 27th 2023

Neoadjuvant/Adjuvant Pembrolizumab Regimen Continues to Show EFS Benefit in High-Risk Early TNBC

Gina Mauro
The 5-year event-free survival EFS) rate was 81.3% with neoadjuvant pembrolizumab/chemotherapy followed by adjuvant pembrolizumab compared with 72.3% in those who received placebo/chemotherapy plus placebo.
Graphic repping 2023's top breast cancer articles
December 24th 2023

Top 5 Most-Read Breast Cancer Articles of 2023

Maggie L. Shaw
In breast cancer coverage this year, topline results from the phase 3 NATALEE trial made waves in March, with our other most-read content in the space covering an expanded indication for abemaciclib, revised screening recommendations, a new potential treatment to reduce radiation exposure, and the benefits of diet and exercise on patient outcomes.
Breast cancer | Image Credit: Crystal Light - stock.adobe.com
December 22nd 2023

Neoadjuvant KN026 Plus Docetaxel Demonstrate Early Activity in HER2+ Breast Cancer

Ryan Scott
A combination of KN026, a novel bispecific antibody, and docetaxel elicited responses with an acceptable toxicity profile when administered as neoadjuvant treatment in patients with HER2-positive (HER2+) early or locally advanced breast cancer.
group of patinets holding a brast cancer awareness ribbon | Image credit: Rawpixel.com - stock.adobe.com
December 18th 2023

Higher Survival Rates Found in Male Hispanic, API Patients With Early Breast Cancer

Brooke McCormick
These findings suggest that addressing socioeconomic disparities and inequities that impact access to health care and services may help improve survival outcomes across racial/ethnic groups of male patients with early breast cancer.
Breast cancer | Image Credit:Science RF - stock.adobe.com
December 15th 2023

Subcutaneous Trastuzumab Induces Immune Function in HER2+ Breast Cancer

Sabrina Serani
Trastuzumab administered subcutaneously delivered unique immunomodulation effects vs intravenous trastuzumab in patients with treatment-naïve HER2-positive (HER2+) breast cancer
Top 5 graphic representing conference highlights
December 11th 2023

ICYMI: Highlights From the ACCC Fall National Oncology Conference

Maggie L. Shaw
This year’s top content from the fall meeting of the Association of Community Cancer Centers (ACCC) highlights both treatment gains made through innovative referral, screening, and assistance initiatives and the ongoing need to improve health equity and research inclusivity.
Representation of breast cancer | Image Credit: Giovanni Cancemi - stock.adobe.com
December 5th 2023

Trastuzumab Biosimilar Gets Go Ahead in EU for HER2+ Breast and Metastatic Gastric Cancers

Kyle Doherty
EG12014, a biosimilar of the anti-HER2 monoclonal antibody trastuzumab, has received a marketing authorization from the European Commission for use in the European Union (EU) for the treatment of patients with HER2-positive (HER2+) breast and metastatic gastric cancer; these are the same indications that trastuzumab holds in the European Union.
Image representing breast cancer | Image credit: vectorfusionart - stock.adobe.com
November 28th 2023

Counseling, Support Areas of Urgent Need Among Mothers With Breast Cancer

Maggie L. Shaw
Data are scarce on the impact that breast cancer among mothers has on their children and their emotional development due to parenting stress and maternal depression.
FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+/HER2– Breast Cancer With PIK3CA, AKT1, or PTEN Alterations
November 20th 2023

FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+/HER2– Breast Cancer With PIK3CA, AKT1, or PTEN Alterations

Chris Ryan
The FDA has approved capivasertib plus fulvestrant for the treatment of patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer harboring 1 or more PIK3CA, AKT1, or PTEN alteration, following progression on at least 1 endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.
Breast Cancer | Image Credit: Axel Kock - stock.adobe.com
November 16th 2023

Lack of Vitamin D May Increase Chemo-Induced Neuropathy Risk in Breast Cancer

Rina Lokaj
Investigators note that prospective research is needed to confirm the efficacy of vitamin D supplements in preventing chemotherapy-induced peripheral neuropathy in patients with breast cancer.
A female doctor sits at her desk and talks to a female patient while looking at her mammogram. Braest cancer prevention | Image Credit: lordn - stock.adobe.com
November 13th 2023

Call to Action Issued for Education on Lesser-Known Breast Cancer Symptoms

Maggie L. Shaw
Some of these symptoms include breast puckering, nipple discharge, and retracted nipple.
Women Value Different Aspects of Care in Breast Reconstruction
November 10th 2023

Women Value Different Aspects of Care in Breast Reconstruction

Julia Bonavitacola
Women of varying backgrounds, educational levels, and marriage status opted for different types of breast reconstruction based on different values.
FDA on textured paper | Image Credit: Araki Illustrations - stock.adobe.com
November 6th 2023

Rhenium Obisbemeda for Breast Cancer, Leptomeningeal Metastases Receives ODD From FDA

Jordyn Sava
Rhenium (186Re) obisbemeda (Plus Therapeutics) shows potential to address the unmet need of new treatment options for patients with breast cancer and leptomeningeal metastases and will continue to be evaluated in the ReSPECT-LM program. The orphan drug designation (ODD) was granted on November 3.
SDOH Social Determinants Of Health Concept - The meeting at the white office table | Image Credit: STOATPHOTO - stock.adobe.com
November 4th 2023

Wide Variation Seen in County-Level Breast Cancer Mortality Linked to SDOH

Maggie L. Shaw
Data from 2176 US counties link obesity and higher breast cancer mortality, while also showing varying degrees of association between mortality and access to healthy lifestyle options per social determinants of health (SDOH).
Afreen Idris Shariff, MD, MBBS, Duke Cancer Institute
November 2nd 2023

Dr Afreen Idris Shariff: Cancer Care Can Transform Through e-Consults

Pearl Steinzor Maggie L. Shaw
Afreen Shariff, MD, MBBS, Duke Cancer Institute, discusses the challenges and benefits of electronic consults (e-consults) for patients with cancer currently undergoing treatment who have a comorbidity history or who develop an endocrine system disorder because of treatment.
Kristine Slam, MD< FACP, Central Ohio Surgical Associates
October 29th 2023

Dr Kristine Slam: Patients With Breast Cancer Must Advocate for Themselves

Maggie L. Shaw
Kristine Slam, MD, FACP, discusses the importance of genetic testing in male patients with breast cancer and why it’s important that all patients with breast cancer advocate for themselves.
Mike Koroscik, MBA, MHA, Allina Health and the Allina Health Cancer Institute
October 26th 2023

Allina Health’s Mike Koroscik on Revolutionizing Early Cancer Detection Through Technology

Pearl Steinzor Maggie L. Shaw
Through the integration of a population health reimbursement model in 2020, Allina Health Cancer Institute was able to implement expanded screening initiatives through the use of artificial intelligence and precision medicine, according to Mike Koroscik, MBA, MHA, vice president of oncology, Allina Health.
Image of women with breast cancer - Vasyl - stock.adobe.com.jpe.jpg
October 25th 2023

Racial, Ethnic Disparities Seen in Breast Cancer Survival, Even Among Clinical Trial Participants

Pearl Steinzor
It is critical to understand the role race and ethnicity play in survival for patients with early-stage breast cancer (eBC), as well as explore potential interventions to close these gaps.
Woman undergoing mammography | Image credit: Peakstock - stock.adobe.com
October 21st 2023

Opt-In vs Opt-Out Patient Outreach Programs Yield Similar Mammography Completion Rates

Skylar Jeremias
No differences in mammography completion were observed between an automated opt-out vs an opt-in patient outreach program for breast cancer screening, according to a randomized controlled trial. However, differences in administration burden between programs could lead clinics to prefer one over the other.
Breast cancer with lymphatics | Image Credit: Axel Kock - stock.adobe.com
October 19th 2023

Low Adherence to Endocrine Therapy Highlights Urgent Need in the Breast Cancer Space

Maggie L. Shaw
Study investigators note their meta-analysis may be the first to demonstrate the importance of interventions to support adherence to adjuvant endocrine therapy for breast cancer.
Kristine Sllam, MD, FACP, Central Ohio Surgical Associates
October 16th 2023

Dr Kristine Slam: In Breast Cancer, Patient Values and Treatment Goals May Differ

Maggie L. Shaw
Kristine Slam, MD, FACP, Central Ohio Surgical Associates, addresses the importance of involving patients in decisions regarding their goals for treatment, emphasizing that this involvement is critical to uncover what they value, as well as their short- and long-term goals for treatment.
Scott Gray, cofounder and CEO, Clincierge | Image Credit: Clincierge
October 11th 2023

Contributor: Advancing Breast Cancer Treatment—The Role of Clinical Trials and the Path Ahead

Scott Gray
Clinical studies have transformed how breast cancer is prevented, identified, and treated. Successful clinical trials improve patient outcomes, so trial administrators must ensure participants receive appropriate support at trial enrollment.
What We’re Reading: Robotic Mastectomies; Racial Discrimination in Maternity Care
October 9th 2023

What We’re Reading: Robotic Mastectomies; Maternity Care Discrimination; Ongoing Kaiser Permanente Strike Issues

AJMC Staff
A minimally invasive procedure could revolutionize breast surgery; Black women experience the worst birthing outcomes; Kaiser Permanente health workers' concerns over labor disputes persist.
FDA on Paper Texture - Araki Illustrations - stock.adobe.com
October 6th 2023

FDA Grants Fast Track Designation to IDE161 for Select Pretreated BRCA1/2-Mutated HR+ Breast Cancer

Kristi Rosa
The FDA has granted fast track designation to IDE161 for use in adult patients with advanced or metastatic hormone receptor–positive, HER2-negative breast cancer harboring BRCA1/2 mutations who have progressed after at least 1 hormonal therapy, a CDK4/6 inhibitor, and a poly (ADP-ribose) polymerase inhibitor.
Kristine Slam, MD, Central Ohio Surgical Associates
October 3rd 2023

Dr Kristine Slam Discusses Preoperative Practices to Increase Treatment Value for Patients With Breast Cancer

Maggie L. Shaw
In this interview from our recent Institute for Value-Based Medicine® event, Kristine Slam, MD, FACP, Central Ohio Surgical Associates, discusses the positive impact that Choosing Wisely and enhanced recovery after surgery, or EROS, protocols have had on patients receiving treatment for breast cancer.
Computer Screen in Hospital Radiology Room: Beautiful Multiethnic Adult Woman Standing Topless Undergoing Mammography Screening Procedure. Screen Showing the Mammogram Scans of Dense Breast Tissues | Image Credit: Gorodenkoff - stock.adobe.com
September 29th 2023

Dato-Dxd Shows Survival Improvements in HR+/HER2– Breast Cancer

Jordyn Sava
The dual primary end points of overall survival and progression-free survival were encouraging when patients with hormone receptor–positive (HR+), HER2-negative (HER2–) breast cancer were treated with datopotamab deruxtecan.
Senior woman having mammography scan at hospital with medical technician. Mammography procedure, breast cancer prevention | Image Credit: Peakstock
September 26th 2023

Older Women Have High Rate of Breast Cancer Overdiagnosis

Maggie L. Shaw
Data from fee-for-service Medicare claims that were linked to the Surveillance, Epidemiology, and End Results program were used for this retrospective cohort analysis among women 70 years and older.
pink mask from COVID19 and breast cancer hold by woman hands | Image Credit Sin Filtro
September 22nd 2023

Breast Cancer Risk Linked to Air Pollution Exposure

Maggie L. Shaw
Data from 6 states—California, Florida, Louisiana, New Jersey, North Carolina, and Pennsylvania—and 2 metropolitan areas—Atlanta, Georgia, and Detroit, Michigan—collected through the National Institutes of Health–AARP Diet and Health Study were used for the investigation.
Kristine Slam, MD, FACP, Central Ohio Surgical Associates
September 19th 2023

Dr Kristine Slam: Value-Based Care in Breast Cancer Requires Collaboration

Maggie L. Shaw
In this interview from our Institute for Value-Based Medicine® event, held in partnership with the Zangmeister Cancer Center of Columbus, Ohio, on September 14, Kristine Slam, MD, FACP, Central Ohio Surgical Associates, discusses the benefits of value-based care in the breast cancer space.
Breast cancer | Image credit: Axel Kock – stock.adobe.com
September 16th 2023

Diet and Exercise Intervention Associated With Better pCR in TNBC or HR+, HER2– BC

Hayley Virgil
Despite seeming to elicit more pathological complete responses (pCRs) in patients with hormone receptor–positive (HR+), HER2-negative triple-negative breast cancer (BC) receiving neoadjuvant chemotherapy, diet and exercise did not affect relative dose intensity.
<12345678
...
12>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo